A dramatic U-turn has taken place, with the FDA now set to review Moderna's mRNA flu vaccine. This unexpected development follows the company's modifications to its application, which initially faced rejection.
The FDA's decision to reconsider Moderna's experimental flu vaccine application comes just a week after its surprising initial rejection. This reversal has sparked a 3% increase in the vaccine maker's shares before the market opened.
Moderna's revised approach has been accepted by the FDA, with the company now seeking full approval for adults aged 50 to 64 and accelerated approval for those 65 and older. Additionally, Moderna plans to conduct a post-marketing study focused on older adults.
The mRNA technology employed in Moderna's Covid vaccines, widely credited for saving countless lives, has sparked controversy due to its association with Health Secretary Robert F. Kennedy Jr., a well-known anti-vaccine activist. Kennedy has been particularly vocal in his criticism of mRNA vaccines.
The regulator initially defended its decision, arguing that Moderna should have administered a higher-strength vaccine to older patients in the control arm of its trial.
Moderna's CEO, Stéphane Bancel, expressed optimism, stating, "Pending FDA approval, we aim to make our flu vaccine accessible to America's seniors later this year, offering them a new way to protect themselves against the flu."
The FDA is expected to make a final decision on this vaccine candidate by August 5th.
This development raises intriguing questions about the future of mRNA technology in vaccine development and its potential impact on public health. What are your thoughts on this controversial topic? Feel free to share your opinions and engage in a respectful discussion in the comments below!
